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Abstract
Background: The Metabolic syndrome (MetS) is an emerging condition worldwide, consistently associated with an
increased risk of several cancers. Some information exists on urothelial carcinoma of the bladder (UCB) and MetS.
This study aims at further evaluating the association between the MetS and UCB.
Methods: Between 2003 and 2014 in Italy, we conducted a hospital-based case-control study, enrolling 690
incident UCB patients and 665 cancer-free matched patients. The MetS was defined as the presence of at least
three of the four selected indicators: abdominal obesity, hypercholesterolemia, hypertension, and diabetes. Odds
ratios (ORs) and corresponding 95 % confidence intervals (CIs) for MetS and its components were estimated
through multiple logistic regression models, adjusting for potential confounders.
Results: Patients with MetS were at a 2-fold higher risk of UCB (95 % CI:1.38–3.19), compared to those without the
MetS. In particular, ORs for bladder cancer were 2.20 (95 % CI:1.42–3.38) for diabetes, 0.88 (95 % CI: 0.66-1.17) for
hypertension, 1.16 (95 % CI: 0.80-1.67) for hypercholesterolemia, and 1.63 (95 % CI:1.22–2.19) for abdominal obesity.
No heterogeneity in risks emerged across strata of sex, age, education, geographical area, and smoking habits.
Overall, 8.1 % (95 % CI: 3.9-12.4 %) of UCB cases were attributable to the MetS.
Conclusions: This study supports a positive association between the MetS and bladder cancer risk.
Keywords: Bladder cancer, Diabetes, Metabolic syndrome, Obesity
Background
Bladder cancer ranks among the 10 highest incident can-
cers worldwide; it is one of the most frequent malignant
tumours of the urinary system, with approximately
420,000 new cases each year among men and women,
and a leading cause of cancer-related deaths [1, 2]. Inci-
dence rates are three-to-four-fold higher in men than in
women, and more than 90 % of cases are urothelial car-
cinoma of the bladder (UCB). In Italy, standardized inci-
dence rates for bladder cancer are 29.9 and 6.2/100,000
among men and women, respectively [3].
Tobacco smoking is a major risk factor for UCB, being
responsible for 30 % to 50 % of cases in both sexes [4].
Other risk factors have been involved in UCB onset,
including obesity, hypertension and diabetes [5–7]. The
strong association with these medical conditions suggests
a possible role of the metabolic syndrome (MetS) in UCB
etiology [6, 7]. The MetS is a complex disorder described
as a cluster of at least three risk factors for cardiovascular
disease, including abdominal obesity, glucose intolerance,
high blood pressure, high triglyceride levels and low high-
density lipoprotein cholesterol levels [8].
The MetS has been consistently associated to increased
risk for several cancers [6], of magnitude ranging from 1.1
to 1.6. Among women, the strongest associations were
reported for endometrial, breast (postmenopausal), pan-
creatic and colorectal cancers [6, 7, 9, 10]. Among men,
the strongest associations were with liver cancer, which
persisted after adjustment for chronic infection with
HBV/HCV [11], renal and colorectal cancer [6, 7, 11, 12].
Although the prevalence of the MetS is increasing
worldwide and high rates of UCB are documented in
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most countries, few epidemiological studies have been
published on the relationship between the MetS and
bladder cancer in the Mediterranean region. Two recent
systematic reviews on the relationship between the MetS
and UCB risk reported a positive association in men
only [6, 7]. Therefore, to provide further information on
the issue in a Mediterranean area, we examined data
from an Italian case-control study investigating potential
risk factors for UCB.
Methods
Between 2003 to 2014, we conducted a case-control
study on urothelial carcinoma of the bladder within an
established Italian network of collaborating centres,
including Aviano and Milan in northern Italy, and
Naples and Catania in southern Italy [13]. Cases were
690 patients aged 25 years or older (median age: 67 year;
range: 25-84 years) with incident UCB admitted to major
general hospitals in the study areas. Nearly all UCB
(n = 642, 93.0 %) were confirmed by histological testing
on tumour tissue specimen from biopsy or surgery. How-
ever, cases whose papillary features could not be deter-
mined (n = 138, 20 %) were excluded from the analysis of
histological subtypes but were included in all other ana-
lyses. Overall, 268 UCB (38.8 %) were non-invasive (i.e.,
TNM pTis/Ta) and 307 (44.5 %) were well or modestly
differentiated.
The control group included 690 patients frequency-
matched to cases according to study centre, sex, and 5-
year age group. Twenty-five controls were excluded after
enrolment because of inappropriate admission diagnosis,
thus leaving 665 eligible controls (median age: 66 years;
range: 27-84 years). Controls were admitted to the same
network of hospitals as cases for a wide spectrum of
acute, non-neoplastic conditions unrelated to tobacco
and alcohol consumption, to known risk factor for UCB,
or to conditions associated to long-term diet modifica-
tion. Overall, 28.9 % of controls were admitted for trau-
matic disorders, 22.1 % for non-traumatic orthopaedic
disorders, 39.3 % for acute surgical conditions, and 9.8 %
for other various illnesses. All study subjects signed an
informed consent. Study protocol was approved by the
Ethic Board of each study hospital (S. Maria degli Angeli
hospital, register trial number 8/2004; and CRO Aviano
National Cancer Institute, protocol number 590/D).
Trained interviewers administered a structured ques-
tionnaire to cases and controls during their hospital stay,
thus keeping refusal below 5 % for both cases and con-
trols. The structured questionnaire collected information
on socio-demographic factors; lifetime smoking and
alcohol drinking habits; dietary habits related to the two
years preceding diagnosis/interview; problem-oriented
medical history; and family history of cancer. Two spe-
cific sections investigated lifetime occupational exposure,
and exposure to chemicals known (or suspected) to be
related to UCB, including the use of hair dyes [13].
Information on clinical diagnosis of diabetes, drug-
treated hypertension, and drug-treated hyperlipidaemia
was self-reported and included age at diagnosis [14].
Diseases whose onset was less than one year before the
interview were not considered. Likewise, self-reported
height and weight one year prior to diagnosis/interview
and at 30 and 50 years of age were collected.
Body mass index (BMI) was computed through the
Quetelet’s formula (weight divided by squared height –
kg/m2). The interviewers measured the waist circumfer-
ence (2 cm above the umbilicus). The presence of
abdominal obesity was defined using the International
Diabetes Federation (IDF) cut-points (waist circumfer-
ence ≥ 94 cm for men and ≥ 80 cm for women). Informa-
tion on waist circumference could not be obtained for
technical reason in 157 cases and 192 controls, thus
leaving 533 cases and 473 controls for the present ana-
lysis shown in Tables 2 and 3. Sensitivity analyses were
further conducted on all cases and controls using BMI ≥
30 kg/m2 as a proxy of abdominal obesity in patients
missing waist circumference. MetS was determined ac-
cording to the 2009 joint interim statement [15], as the
presence of at least three of the following components:
abdominal obesity, diabetes, drug-treated hypertension
(as a proxy of elevated blood pressure), and drug-treated
hyperlipidaemia (as a proxy of high triglyceride levels).
Odds ratios (ORs) and the corresponding 95 % confi-
dence intervals (CIs) were calculated by means of uncon-
ditional logistic regression models, including terms for
study centre, sex, 5-year age groups, years of education
(i.e., <7, 7-11, ≥12) as a proxy of social status. To adjust
for potential confounders (i.e. factors associated to both
outcome and exposure), smoking habits (never; former;
current: <20; 20+ cigarettes/day) were further included in
the model. The test for trend was based on the likelihood-
ratio test between the models with and without the linear
term, reporting the median values in each strata of the
variable of interest. Percent attributable risks (PAR) were
computed using the distribution of risk factors among
UCB cases [16].
Results
Most UCB cases were men and aged ≥65 years (Table 1).
Cases and controls reported similar education, whereas
current tobacco smoking was more frequent among
UCB cases than controls (39.8 % and 21.7 %, respectively).
Compared to never smokers, subjects smoking ≥20 ciga-
rettes/day showed a seven-fold increased in UCB risk
(95 % CI: 4.94-11.41), with a significant risk trend for
number of cigarettes (P < 0.01).
Compared with people without any MetS components,
the ORs were 2.00 (95 % CI: 1.17-3.41) for those with
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three components and 7.93 (95 % CI: 1.71-36.79) for
those with four components (P for trend < 0.01). After
adjustment for the other MetS components, patients
with diabetes (16.9 % cases and 8.0 % controls) showed a
two-fold increase in UCB risk (95 % CI: 1.42-3.38 -
Table 2). Likewise, patients reporting abdominal obesity
showed a significantly higher UCB risk (OR = 1.63; 95 %
CI: 1.22-2.19). No significant association emerged for
treated hypertension (OR = 0.88; 95 % CI: 0.66-1.17) and
treated hyperlipidaemia (OR = 1.16; 95 % CI: 0.80-1.67).
Compared to patients without indication of MetS
(i.e., with two or less MetS indicators), those with
MetS reported a two-fold increase in UCB risk (95 %
CI: 1.38-3.19 - Table 2). Accordingly, in this study
population, 8.1 % (95 % CI: 3.9-12.4 %) of all UCB
cases were attributable to MetS (data not shown).
Furthermore, 54 UCB cases (65.1 %) and 16 controls
(38.1 %) with MetS reported diabetes; among these,
the risk of UCB was 3.63 (95 % CI: 1.99-6.61) compared
to those without MetS (Table 2). People with MetS with-
out diabetes still showed a 16 % increased risk of UCB,
but the association was not statistically significant.
The association between the MetS and UCB risk was
similar in strata of gender (men vs. women; P for hetero-
geneity = 0.08), age (<65 years vs. ≥65 years; P = 0.59),
education (<7 vs. ≥7 years; P = 0.92), geographical area
(North vs. South of Italy; P = 0.43), and smoking habits
(never, ever <20 cigarettes/day, and ever ≥20 cigarettes/
day; P = 0.51 - Table 3). The association between the
MetS and UCB risk was stronger (P = 0.03) for papillary
UCB (OR = 2.61; 95 % CI: 1.68-4.04) than for non-
papillary UCB (OR = 0.86; 95 % CI: 0.36-2.09), whereas
no difference emerged according to tumour invasiveness
(pTa/Tis vs. pT1-T4; P = 0.69 - Table 3). These results
did not remarkably change using BMI ≥ 30 kg/m2 when
the information of waist circumference was missing
(data not shown).
Discussion
The present study supports a positive association between
the MetS and risk of UCB, with a possible stronger associ-
ation for papillary UCB. Conversely, no significant differ-
ence emerged according to gender, age, education,
geographical area, and smoking habits. These findings are
particularly interesting, giving the increasing prevalence of
MetS worldwide and the attention by the scientific com-
munity on its effects on various health outcomes, includ-
ing bladder and other urological cancers [6, 17].
In a prospective cohort study of 580 000 people – carried
out within the Me-Can study – Haggstrom et al. [18]
showed that MetS was associated with a significantly in-
creased risk of UCB in men (RR = 1.10; 95 % CI: 1.01–1.18
for each incremental MetS unit), whereas no association
was observed in women. Similarly, an Italian population-
based study [19] observed a modest, non significant, in-
creased risk of UCB only in men concurrently treated with
antihyperglycaemic, antihypertensive, and hypolipidemic
drugs. In their meta-analysis, Esposito et al. estimated that,
in men, the presence of the MetS was significantly associ-
ated with the presence of UCB with a RR of 1.10 (95 % CI:
1.02–1.18) [11]. Our findings seem therefore to confirm
Table 1 Distribution of cases of urothelial carcinoma of the
bladder (UCB) and controls, odds ratio (OR) and corresponding
95 % confidence interval (CI) according to socio-demographic
characteristics and tumor variables. Italy, 2003-2014
Variables UCB Cases Controls OR (95 % CI)a
n (%) n (%)
Sex
Men 595 (86.2) 561 (84.4)
Women 95 (13.8) 104 (15.6)
Age (years)
<55 83 (12.0) 105 (15.8)
55-59 65 (9.4) 73 (11.0)
60-64 107 (15.5) 119 (17.9)
65-69 164 (23.8) 147 (22.1)
70-74 155 (22.5) 124 (18.7)
≥75 116 (16.8) 97 (14.6)
Study centre
Aviano 242 (35.1) 250 (37.6)
Milan 241 (34.9) 238 (35.8)
Naples 129 (18.7) 100 (15.0)
Catania 78 (11.3) 77 (11.6)
Education (years)b
<7 292 (42.3) 273 (41.1) Ref
7-11 224 (32.5) 215 (32.3) 1.10 (0.85-1.44)
≥12 173 (25.1) 177 (26.6) 1.02 (0.76-1.36)
χ2 for trend; p-value 0.03; P = 0.86
Smoking habitb
Never 96 (13.9) 237 (35.6) Ref
Former 310 (44.9) 284 (42.7) 2.80 (2.06-3.80)
Current
<20 cig./day 143 (20.7) 87 (13.1) 4.81 (3.32-6.98)
≥20 cig./day 132 (19.1) 57 (8.6) 7.51 (4.94-11.41)
χ2 for trend; p-value 103.28; P < 0.01
Histological subtype
Non-papillary 103 (14.9)
Papillary 449 (65.1)
Not determinable 138 (20.0)
aAdjusted for sex, age (<55; 55-59; 60-64; 65-69; 70-74; ≥75 years), and study
centre; bThe sum does not add up to the total because of missing values
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this association with a substantially stronger OR as com-
pared to previous studies [6, 7].
Mechanisms that link MetS and cancer risk are not
fully understood. However, some MetS components have
been extensively investigated as cancer risk factors.
There is mounting evidence showing the negative influence
of obesity on genitourinary malignancies [20]. Several
epidemiological studies showed a positive relationship
between obesity and an increased risk of UCB, although
others did not find any significant associations [21, 22]. Al-
though BMI is generally used to define the grade of obesity,
in our study we used abdominal obesity since it better
explains obesity-related health risk [23]. Moreover a recent
study used visceral obesity as individual component of
MetS to predict adverse pathological features in UCB [24].
The biological mechanism for obesity-related carcino-
genesis is not yet well characterized, but many possibilities
have been suggested. High levels of adipose tissue correlate
with high levels of cholesterol, a precursor for the andro-
gen testosterone, which stimulates epithelial cell prolifera-
tion. High adipose levels have also been correlated with
high plasma levels of vascular endothelial growth factor
(VEGF), which both stimulate proliferation of epithelial
cells. Adipose tissue also secretes leptin, which has been
implicated in enhancing angiogenesis and, consequently,
may also enhance tumour development [25]. Adiposity has
also been associated with reduced mitochondrial function
and, in turn, increased circulating reactive oxygen species,
which can cause DNA damage [26].
The strongest single risk factor found in the present
study was diabetes mellitus. Nonetheless, people with
the MetS but without diabetes had a 16 % increased risk
of UCB. Furthermore, Table 2 shows a doubling of UCB
risk in people with 4 MetS components (OR = 7.93; CI:
Table 2 Distribution of cases of urothelial carcinoma of the bladder (UCB) and controls, odds ratio (OR) and corresponding 95 %
confidence interval (CI), according to indicators of metabolic syndrome (MetS). Italy, 2003-2014
Components UCB Cases Controls OR (95 % CI)a OR (95 % CI)b
n (%) n (%)
Diabetes mellitus
No 443 (83.1) 435 (92.0) Ref Ref
Yes 90 (16.9) 38 (8.0) 2.22 (1.45-3.39) 2.20 (1.42-3.38)
Drug-treated hypertension
No 316 (59.3) 279 (59.0) Ref Ref
Yes 217 (40.7) 194 (41.0) 0.99 (0.75-1.31) 0.88 (0.66-1.17)
Drug-treated hyperlipidaemia
No 442 (82.9) 399 (84.4) Ref Ref
Yes 91 (17.1) 74 (15.6) 1.21 (0.84-1.73) 1.16 (0.80-1.67)
Abdominal obesityc
No 145 (27.2) 167 (35.3) Ref Ref
Yes 388 (72.8) 306 (64.7) 1.65 (1.23-2.21) 1.63 (1.22-2.19)
Nr. of MetS components
None 83 (15.6) 85 (18.0) Ref
1 213 (40.0) 208 (44.0) 1.03 (0.70-1.51)
2 154 (28.9) 138 (29.2) 1.23 (0.81-1.85)
3 67 (12.6) 40 (8.5) 2.00 (1.17-3.41)
4 16 (3.0) 2 (0.4) 7.93 (1.71-36.79)
χ2 for trend; p-value 11.45; P < 0.01
Increment of 1 MetS component 1.29 (1.11-1.49)
Indicators of MetSd
No 450 (84.4) 431 (91.1) Ref
Yes 83 (15.6) 42 (8.9) 2.09 (1.38-3.19)
"Without diabetes" 29 (5.4) 26 (5.5) 1.16 (0.65-2.07)
"With diabetes" 54 (10.1) 16 (3.4) 3.63 (1.99-6.61)
aAdjusted for sex, age (<55; 55-59; 60-64; 65-69; 70-74; ≥75 years), study centre, education (<7; 7-11; ≥12 years), and tobacco smoking (never; former; current: <20;
20+ cigarettes/day); bSeparate components were additionally adjusted for the other MetS components; cAccording to IDF cut-points for waist circumference.
dDefined as the presence of at least three out of four MetS components
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1.71-36.79) than in people with diabetes (OR = 3.63; CI:
1.99-6.61) suggesting that the MetS indeed plays a rele-
vant role in the risk of UCB.
Previous cohort studies have investigated the associ-
ation between diabetesand UCB risk [27–31]. All these
studies reported an increased UCB risk for both men
and women with diabeteslevels, but strongest associa-
tions were seen with longer diabetes duration [27,]. The
Me-Can study reported a statistically significant in-
creased risk among women, with an RR of 1.45 (95 %
CI: 1.05–2.01) per mmol increment of glucose [32]. A
possible additional pathway between diabetes and UCB
risk is the increased incidence of urinary tract infections
among subjects with diabetes [30]. Among separate
components of MetS, high blood pressure and hyper-
cholesterolemia were not significantly associated with
the risk of UCB in our study. These findings are consist-
ent with those of previous prospective studies [6, 18].
Possible study limitations included selection and infor-
mation bias. The proportion of pTa/Tis in our case
series (45.3 %) is slightly lower than expected (approxi-
mately 60 %), thus limiting the generalization of our
results. However, similar associations were found for
pTa/Tis and pT1-T4 UCB, suggesting that this type of
selection bias had a limited impact on our results. Infor-
mation on MetS components was based on self-reported
data from a questionnaire, which collected history of dia-
betes, treated hypertension, and treated hyperlipidaemia,
rather than direct measurements of fasting plasma glu-
cose, blood pressure, triglycerides and HDL cholesterol.
Underestimation of the prevalence of MetS may therefore
have occurred. However, reliability of our questionnaire
on diabetes was tested among almost 300 subjects who
were interviewed twice, reporting a satisfactory agreement
(k statistic = 0.85) [14]. Moreover, a recent cohort study
from Spain showed that self-reported data on MetS indi-
cators and on MetS itself are sufficiently accurate for
epidemiological inference [32]. Likewise, validation studies
of hypertension confirmed with a medical examination
found a reasonable accuracy of self-reported information
Table 3 Odds ratio (OR) and corresponding 95 % confidence interval (CI) for urothelial carcinoma of the bladder (UCB), according to
indicators of the metabolic syndrome (MetS) in strata of selected variables. Italy, 2003-2014
Variables Indicator of MetS OR (95 % CI)a χ2 for
heterogeneity;
p-value
No Yes
Ca:Co Ca:Co
Sex
Men 381:359 75:32 2.49 (1.56-3.96)
Women 69:72 8:10 0.81 (0.25-2.60) 3.08; P = 0.08
Age (years)
<65 183:199 25:14 2.53 (1.21-5.29)
≥65 267:232 58:28 1.97 (1.18-3.29) 0.31; P = 0.59
Education (years)b
<7 178:185 43:24 2.07 (1.14-3.75)
≥7 271:246 40:18 2.16 (1.17-3.97) 0.01; P = 0.92
Geographical area
North 307:311 64:31 2.31 (1.42-3.74)
South 143:120 19:11 1.56 (0.66-3.67) 0.61; P = 0.43
Smoking habitb
Never 67:150 7:16 1.16 (0.43-3.14)
Ever <20 cig./day 190:174 34:13 2.45 (1.23-4.91)
Ever ≥20 cig./day 186:104 41:13 1.85 (0.93-3.70) 1.37; P = 0.51
Histological subtypeb
Non-papillary 82:431 7:42 0.86 (0.36-2.09)
Papillary 299:431 69:42 2.61 (1.68-4.04) 4.82; P = 0.03
Invasivenessb
pTa/Tis 183:431 41:42 2.32 (1.42-3.79)
pT1-T4 221:431 38:42 2.13 (1.28-3.57) 0.16; P = 0.69
aAdjusted for sex, age (<55; 55-59; 60-64; 65-69; 70-74; ≥75 years), study centre, education (<7; 7-11; ≥12 years), and tobacco smoking (never; former; current: <20;
20+ cigarettes/day); bThe sum does not add up to the total because of missing values
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[33]. Other self-reported MetS indicators might have been
underestimated, but such information bias is likely to have
occurred similarly in cases and controls, and, conse-
quently, should have led to an attenuation of the real asso-
ciation [16, 34].
Other potential limitations of this study design comprise
recall bias, since cases might have been more sensitized
than controls to report history of disease. The hospital set-
ting should have, however, improved information compar-
ability of cases to controls, because both groups were
interviewed under similar conditions and were therefore
similarly sensitized toward recalling medical history. How-
ever, cases and controls were enrolled from the same
catchment areas, and careful attention was paid to exclude
from the control group subjects admitted for any condi-
tion related to the exposures under study, including
tobacco smoking. Furthermore, results were consistent
when analyses were performed excluding, in turn, the
main diagnostic categories of controls. On the other hand,
our findings were strengthened by the nearly complete
participation of identified cases and controls, and by the
use of a validated, reproducible questionnaire [14].
Conclusion
Our data suggest that metabolic aberrations related to
the MetS, which are known to increase the risk of sev-
eral types of cancer, also increase the risk of UCB. Both
the worldwide increasing MetS prevalence and the rising
incidence of UCB suggest that each year a considerable
fraction of this cancer is attributable to the MetS. Thus,
evidence is needed to investigate whether effective inter-
ventions to reduce the prevalence of the MetS in adult
populations could reduce UCB risk. Moreover, patients
with the MetS, even in presence of obesity and/or dia-
betes, should be encouraged to follow appropriate cancer
control strategies.
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